[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms


Description

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

Trial Eligibility

Inclusion Criteria: * Age ≥ 18 years * Participants with intermediate-1 or higher risk PMF, post-PV, of post-ET MF, histologically confirmed * Evidence of minimum burden of disease based on symptoms and/or splenomegaly * Life expectancy \> 6 months * Willingness to undergo a pretreatment and regular on-study bone marrow biopsies and aspirations (as appropriate to disease) * Existing documentation of JAK2V617F mutation from a qualified local laboratory * Previously treated with at least 1 JAK inhibitor for ≥ 12 weeks and resistant, refractory, intolerant to, or have lost response to JAK inhibitor treatment Exclusion Criteria: * Presence of a hematological malignancy requiring treatment, other than PMF, post-PV MF, or post-ET MF * Prior history of major bleeding or thrombosis within the 3 months prior to study enrollment * Participants with abnormal hematologic, hepatic, or renal function based on laboratory evaluation * Has undergone prior allogenic or autologous stem-cell transplantation or allogenic stem-cell transplantation is planned * Active invasive malignancy * Significant concurrent, uncontrolled medical condition * Active HBV/HCV or known HIV * Any prior MF-directed therapy within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment * Participants undergoing treatment with G-CSF or GM-CSF, romiplostim, or eltrombopag at any time within 4 weeks before the first dose of study treatment Other protocol-defined Inclusion/Exclusion Criteria may apply.

Study Info

Organization

Incyte Corporation


Primary Outcome

Number of participants with Dose Limiting Toxicities (DLTs)


Outcome Timeframe Up to 28 days

NCTID NCT06313593

Phases PHASE1

Primary Purpose TREATMENT

Start Date 2024-08-08

Completion Date 2027-06-06

Enrollment Target 66

Interventions

DRUG INCB160058

Locations Recruiting

Stanford University

United States, California, Palo Alto


Northwestern University

United States, Illinois, Chicago


The University of Kansas Cancer Center Kucc University of Kansas Clinical Research Center

United States, Kansas, Fairway


Dana Farber Cancer Institute

United States, Massachusetts, Boston


Icahn School of Medicine At Mount Sinai

United States, New York, New York


Interested in joining this trial?

Our dedicated patient navigators are here to support you by reviewing the eligibility criteria to see if you might qualify for this trial.

newsletter icon

Get the latest thought leadership on your Myelofibrosis delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Thanks to our HealthTree Community for Myelofibrosis Sponsors:

regeneron
Karyopharm Therapeutics

Follow Us

facebook instagram youtube